Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Shares of Hims & Hers Health Inc ( HIMS 17.50%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...

Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...